Johansson Linda, Ärlestig Lisbeth, Kokkonen Heidi, Brink Mikael, Rantapää-Dahlqvist Solbritt
Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden.
Rheumatology (Oxford). 2017 Dec 1;56(12):2190-2196. doi: 10.1093/rheumatology/kex339.
RANK ligand (RANKL) is involved in destruction and osteoporosis in RA. In this study, the relationships between RANKL and ACPA, anti-carbamylated protein antibodies (anti-CarP), cytokines and chemokines were analysed in individuals before the onset of RA symptoms, and their associations with radiological findings at disease onset were assessed.
This was a case-control study performed within the Medical Biobank of Northern Sweden that included 470 pre-symptomatic individuals [334 women and 136 men; mean (s.d.) age 52.3 (9.4) years] using blood samples donated before symptom onset (pre-dating time; 5.0 years) and 96 controls (60 women and 36 men). Plasma was analysed for RANKL (BioVendor, Karasek, Brno, Czech Republic), anti-CCP2 antibodies (Eurodiagnostics, Malmö, Sweden), anti-CarP antibodies (in-house ELISA), ACPA specificities (ISAC-platform, Phadia AB, Uppsala, Sweden) and cytokines/chemokines (Meso Scale Discovery methods, Rockville, MD, USA). Radiographs of hands and feet were graded using the Larsen score.
The concentration of RANKL was higher in the pre-symptomatic individuals compared with controls; mean (s.e.m.): 0.50 (0.03) vs 0.22 (0.02) nmol/l (P < 0.001). The concentration increased gradually over time until symptom onset but appeared later than ACPA/RF/anti-CarP antibodies. Positivity for these antibodies yielded higher levels of RANKL compared with seronegativity (P < 0.001). RANKL concentrations were significantly associated with IL-6 and IL-10 concentrations. The combination of positivity for RANKL and anti-CarP antibodies resulted in a higher Larsen score at diagnosis β = 6.18 (95% CI: 0.93, 11.43; P = 0.022).
RANKL concentrations were increased several years before symptom onset for RA, particularly in ACPA/RF/anti-CarP-positive individuals, all detectable earlier than RANKL. Positivity for RANKL and anti-CarP antibodies yielded the highest Larsen score at disease onset.
核因子κB受体活化因子配体(RANKL)参与类风湿关节炎(RA)的骨质破坏和骨质疏松。在本研究中,分析了RA症状出现前个体中RANKL与抗环瓜氨酸肽抗体(ACPA)、抗瓜氨酸化蛋白抗体(抗CarP)、细胞因子和趋化因子之间的关系,并评估了它们与疾病发作时放射学表现的相关性。
这是一项在瑞典北部医学生物库中进行的病例对照研究,纳入了470名症状出现前的个体[334名女性和136名男性;平均(标准差)年龄52.3(9.4)岁],使用症状出现前(提前时间;5.0年)捐献的血样,以及96名对照者(60名女性和36名男性)。分析血浆中的RANKL(BioVendor公司,捷克布尔诺卡拉塞克)、抗环瓜氨酸肽2抗体(Eurodiagnostics公司,瑞典马尔默)、抗CarP抗体(内部酶联免疫吸附测定)、ACPA特异性(ISAC平台,瑞典乌普萨拉法迪亚公司)和细胞因子/趋化因子(美国马里兰州罗克维尔的Meso Scale Discovery方法)。使用拉森评分对手足X线片进行分级。
与对照组相比,症状出现前个体中RANKL的浓度更高;平均(标准误):0.50(0.03) vs 0.22(0.02)nmol/l(P < 0.001)。该浓度随时间逐渐升高直至症状出现,但比ACPA/RF/抗CarP抗体出现得晚。与血清阴性相比,这些抗体阳性时RANKL水平更高(P < 0.001)。RANKL浓度与白细胞介素-6(IL-6)和白细胞介素-10(IL-10)浓度显著相关。RANKL和抗CarP抗体阳性的组合在诊断时导致更高的拉森评分β = 6.18(95%可信区间:0.93,11.43;P = 0.022)。
RA症状出现前数年RANKL浓度升高,特别是在ACPA/RF/抗CarP阳性个体中,所有这些在RANKL之前均可检测到。RANKL和抗CarP抗体阳性在疾病发作时产生最高的拉森评分。